Colleen Anderson

European, randomized, phase 3 study of lisdexamfetamine dimesylate in children and adolescents with attention-deficit/hyperactivity disorder

David Coghill, Tobias Banaschewski, Michel Lecendreux et al. · European Neuropsychopharmacology · 2013 · 122 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +17

Efficacy and Safety of Lisdexamfetamine Dimesylate and Atomoxetine in the Treatment of Attention-Deficit/Hyperactivity Disorder: a Head-to-Head, Randomized, Double-Blind, Phase IIIb Study

Esther Cardo, Péter Nagy, Colleen Anderson et al. · CNS Drugs · 2013 · 87 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +17

Lisdexamfetamine Dimesylate Augmentation in Adults With Persistent Executive Dysfunction After Partial or Full Remission of Major Depressive Disorder

Manisha Madhoo, Richard S.E. Keefe, Robert M. Roth et al. · Neuropsychopharmacology · 2013 · 73 citations

Medicine, Pharmacology, Psychiatry +16

Maintenance of Efficacy of Lisdexamfetamine Dimesylate in Children and Adolescents With Attention-Deficit/Hyperactivity Disorder: Randomized-Withdrawal Study Design

David Coghill, Tobias Banaschewski, Michel Lecendreux et al. · Journal of the American Academy of Child & Adolescent Psychiatry · 2014 · 56 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +17

A Post Hoc Comparison of the Effects of Lisdexamfetamine Dimesylate and Osmotic-Release Oral System Methylphenidate on Symptoms of Attention-Deficit Hyperactivity Disorder in Children and Adolescents

César A. Soutullo, Tobias Banaschewski, Michel Lecendreux et al. · CNS Drugs · 2013 · 44 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +17